The global bilirubin testing market size was estimated at USD 2.16 billion in 2025 and is projected to reach USD 2.94 billion by 2033, growing at a CAGR of 4.04% from 2026 to 2033. The market is experiencing a transformative phase, driven by an urgent need for early diagnostic tools in neonatal care and the rising prevalence of liver-related diseases.
Recently, there is a significant pivot toward point-of-care (POC) testing, with new microfluidic devices achieving over 90% sensitivity in clinical trials. These innovations are largely propelled by the increasing incidence of neonatal jaundice, which affects nearly 60% of full-term infants, and the global surge in chronic liver conditions such as Nonalcoholic Fatty Liver Disease (NAFLD).
Strategic moves by industry leaders, including the integration of automated high-throughput analyzers in diagnostic labs, are streamlining workflows and reducing the time-to-result from hours to minutes. This evolution is further supported by updated clinical guidelines from organizations like the American Academy of Pediatrics (AAP), which advocate for more rigorous screening protocols to prevent kernicterus, thereby cementing bilirubin testing as a non-negotiable standard in modern pediatric healthcare.
In July 2025, a pilot study reported the development of a new microfluidic-based point-of-care device for bilirubin testing that demonstrated strong correlation (R² = 0.986) with standard laboratory methods, along with high sensitivity (90%) and specificity (97%) in classifying clinically relevant bilirubin levels. Designed with portable optoelectronic sensing technology, the device aims to provide accurate, rapid testing outside traditional laboratory settings, particularly benefiting neonatal jaundice screening and liver function assessment in decentralized or resource-limited environments. Although validated on a small sample size and requiring broader clinical studies, the innovation supports the expansion of point-of-care diagnostics, increases accessibility to bilirubin testing, and is likely to drive growth in the decentralized and neonatal diagnostics segments of the market.
One of the most significant developments in the market scope is the rapid adoption of transcutaneous bilirubinometry (TcB) and smartphone-based diagnostic applications. Traditionally, bilirubin levels were measured via invasive "heel stick" blood draws, which cause significant distress to neonates and carry risks of infection. However, the market is now shifting toward light-based, non-invasive sensors that provide instantaneous readings through the skin. Emerging research into Artificial Intelligence (AI) and machine learning has introduced 1D Convolutional Neural Networks capable of analyzing smartphone images of an infant's skin or eyes to predict bilirubin levels with near-clinical accuracy. This technological leap not only enhances patient comfort but also expands the market’s reach into home-based monitoring and remote healthcare settings, allowing parents and clinicians to track jaundice levels without frequent hospital visits.
This product will be delivered within 1-3 business days.
Recently, there is a significant pivot toward point-of-care (POC) testing, with new microfluidic devices achieving over 90% sensitivity in clinical trials. These innovations are largely propelled by the increasing incidence of neonatal jaundice, which affects nearly 60% of full-term infants, and the global surge in chronic liver conditions such as Nonalcoholic Fatty Liver Disease (NAFLD).
Strategic moves by industry leaders, including the integration of automated high-throughput analyzers in diagnostic labs, are streamlining workflows and reducing the time-to-result from hours to minutes. This evolution is further supported by updated clinical guidelines from organizations like the American Academy of Pediatrics (AAP), which advocate for more rigorous screening protocols to prevent kernicterus, thereby cementing bilirubin testing as a non-negotiable standard in modern pediatric healthcare.
In July 2025, a pilot study reported the development of a new microfluidic-based point-of-care device for bilirubin testing that demonstrated strong correlation (R² = 0.986) with standard laboratory methods, along with high sensitivity (90%) and specificity (97%) in classifying clinically relevant bilirubin levels. Designed with portable optoelectronic sensing technology, the device aims to provide accurate, rapid testing outside traditional laboratory settings, particularly benefiting neonatal jaundice screening and liver function assessment in decentralized or resource-limited environments. Although validated on a small sample size and requiring broader clinical studies, the innovation supports the expansion of point-of-care diagnostics, increases accessibility to bilirubin testing, and is likely to drive growth in the decentralized and neonatal diagnostics segments of the market.
One of the most significant developments in the market scope is the rapid adoption of transcutaneous bilirubinometry (TcB) and smartphone-based diagnostic applications. Traditionally, bilirubin levels were measured via invasive "heel stick" blood draws, which cause significant distress to neonates and carry risks of infection. However, the market is now shifting toward light-based, non-invasive sensors that provide instantaneous readings through the skin. Emerging research into Artificial Intelligence (AI) and machine learning has introduced 1D Convolutional Neural Networks capable of analyzing smartphone images of an infant's skin or eyes to predict bilirubin levels with near-clinical accuracy. This technological leap not only enhances patient comfort but also expands the market’s reach into home-based monitoring and remote healthcare settings, allowing parents and clinicians to track jaundice levels without frequent hospital visits.
Global Bilirubin Testing Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global bilirubin testing market report based on product, technology, application, patient, end use, and region:Product Outlook (Revenue, USD Million, 2021-2033)
- Bilirubin Reagent Kits and Assay Consumables
- Calibrators and Quality Controls
- Test Cartridges and Strips
- Dedicated Blood Bilirubin Analyzers
Technology Outlook (Revenue, USD Million, 2021-2033)
- Laboratory-Based Testing
- POC Testing
Application Outlook (Revenue, USD Million, 2021-2033)
- Neonatal Jaundice Screening and Monitoring
- Liver Function Testing (LFT)
- Hemolytic Disorders Assessment
- Routine & Pre-operative Health Screening
Patient Outlook (Revenue, USD Million, 2021-2033)
- Neonates
- Pediatric Patients
- Adults
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals & NICUs
- Diagnostic Laboratories
- Maternity and Neonatal Clinics
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Spain
- Italy
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Bilirubin Testing Market Variables, Trends, & Scope
Chapter 4. Bilirubin Testing Market: Product Estimates & Trend Analysis
Chapter 5. Bilirubin Testing Market: Technology Estimates & Trend Analysis
Chapter 6. Bilirubin Testing Market: Application Estimates & Trend Analysis
Chapter 7. Bilirubin Testing Market: Patients Estimates & Trend Analysis
Chapter 8. Bilirubin Testing Market: End Use Estimates & Trend Analysis
Chapter 9. Bilirubin Testing Market: Regional Estimates & Trend Analysis
Chapter 10. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Siemens Healthineers AG
- Abbott
- Beckman Coulter, Inc.
- Randox Laboratories Ltd.
- SEKISUI Diagnostics
- Fortress Diagnostics
- Agappe Diagnostics Ltd.
- Nova Biomedical.
- Radiometer Medical ApS.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 320 |
| Published | March 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 2.16 Billion |
| Forecasted Market Value ( USD | $ 2.94 Billion |
| Compound Annual Growth Rate | 4.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
